Cybin announced that it has completed enrollment in its Phase 2 study of CYB003, a proprietary deuterated psilocybin analog program being developed for the potential treatment of major depressive disorder, or MDD. All participants in the final cohort have received at least one dose with several second doses already administered, and no serious adverse events observed in participants.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CYBN: